Cytokinetics
CYTK
#2270
Rank
$6.84 B
Marketcap
$57.98
Share price
3.83%
Change (1 day)
78.40%
Change (1 year)

P/E ratio for Cytokinetics (CYTK)

P/E ratio as of November 2024 (TTM): -10.2

According to Cytokinetics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -10.1898. At the end of 2022 the company had a P/E ratio of -10.8.

P/E ratio history for Cytokinetics from 2004 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2022-10.8-33.06%
2021-16.155.79%
2020-10.3105.6%
2019-5.0355.15%
2018-3.242.2%
2017-3.17-109.92%
201632.0-396.51%
2015-10.8-42.11%
2014-18.6281.16%
2013-4.89196.19%
2012-1.6524.9%
2011-1.32-50.7%
2010-2.68-137.75%
20097.10-383.9%
2008-2.50-45.56%
2007-4.59-4.23%
2006-4.798.84%
2005-4.4161.6%
2004-2.73

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
77.2-857.91%๐Ÿ‡บ๐Ÿ‡ธ USA
-0.4196-95.88%๐Ÿ‡บ๐Ÿ‡ธ USA
-0.0676-99.34%๐Ÿ‡บ๐Ÿ‡ธ USA
23.0-325.60%๐Ÿ‡บ๐Ÿ‡ธ USA
11.8-216.23%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.